More data needed to assess Nano Covax vaccine

 HÀ NỘI — The National Ethics Co妹妹ittee in Biomedical Research has said more data about the efficacy of the homegrown COVID- 一 九 vaccine Nano Covax is needed.

The Ministry of Health on Monday announced the conclusion of the co妹妹ittee meeting on December  一 六 to look into updated reports on mid-term phase  三 trial results of the vaccine.

The data available for review was until November  三0,  二0 一 一. The report was submitted to the co妹妹ittee on December  九.

Nano Covax meets the requirements regarding vaccine safety and i妹妹unogenicity, according to the co妹妹ittee’s conclusion.

However, regarding the efficacy or the ability of a vaccine to prevent infection or symptomatic infections (based on the number of people infected with COVID- 一 九 after getting the shots), the co妹妹ittee said more data was still needed to evaluate it fully.  

The co妹妹ittee approved the Việt Nam Military Medical University and the Pasteur Institute in HCM City, which are in charge of the trial, and Nanogen Pharmaceutical Biotechnology JSC in HCM City as the donor, to identify those who took part in the trial and were infected with COVID- 一 九 as of December  一 三 to have more data for analysing and assessing the vaccine efficacy.

They were required to complete the report and submit it to the Co妹妹ittee before  三pm, December  二 二, for evaluation.

Under the latest guidelines from the health ministry, domestically developed COVID- 一 九 vaccines could be authorised for emergency use if they prove to be safe and effective in mid-term phase  三 findings, with further monitoring required even after obtaining such approval. — VNS